1–10 of 205 results for AMD-Neovascular
Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study
Emmanuel Chang, MD PhD FACS FASRS
Annual Meeting Talks
2023
Early Treatment Patterns and Outcomes in Patients With Neovascular Age-Related Macular Degeneration Initiating Faricimab: The FARETINA-AMD Study
Theodore Leng, MD, MS, FASRS
Faricimab Rapidly Improves Fluid Parameters in Patients With nAMD
Nikolas JS London, MD, FACS, FASRS
Additional Visual and Anatomic Outcomes of Intravitreal Aflibercept Injection, 8 mg vs 2 mg: Post Hoc Analysis of the Phase 2 CANDELA Study
Priya Sharma Vakharia, MD
Exudative Age-Related Macular Degeneration Events from the OAKS and DERBY Clinical Trials of Pegcetacoplan in Geographic Atrophy
Roger A. Goldberg, MD, MBA
Daily Imaging With Home Optical Coherence Tomography Among Treatment-Naive Neovascular Age-Related Macular Degeneration Participants
Kevin J. Blinder, MD, FASRS
Accuracy and Residual Volume of Commonly Used Syringes for Intravitreal Injection and the Impact on Intraocular Pressure
Gustavo Barreto de Melo, MD, PhD, FASRS
Safety and Tolerability of Suprachoroidal Injection of CLS-AX in Neovascular AMD Patients With Persistent Activity After Anti-VEGF Therapy
Rahul N. Khurana, MD, FASRS
Long-Term Efficacy and Safety of the Port Delivery System With Ranibizumab in Patients With nAMD: Results of the Portal 5-year Subgroup Analysis
David J Massop, MD
Subgroup Analyses of the Phase 1 DAVIO Trial of EYP-1901 Showing Reduced Treatment Burden in Wet Age-related Macular Degeneration
Philip P Storey, MD, MPH